Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Leerink Affirms Ironwood Pharma (IRWD) at 'Market Perform'; No Catalyst Seen in Next 12 - 18 Months
November 4, 2015 9:09 AM ESTLeerink affirms Ironwood Pharma (Nasdaq: IRWD) with a Market Perform rating and $12 price target following Q3 results issued Tuesday night.
Analyst Jason Gerberry commented, IRWD reported 3Q Linzess sales of ~$117 million coming in modestly below our est. of ~$121 million. The miss was modest, and we dont... More
Ironwood Pharma (IRWD) Misses Q3 EPS by 5c
November 3, 2015 4:23 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.25), $0.05 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $39.6 million versus the consensus estimate of $41.76 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More